Masayo Sakabe
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masayo Sakabe.
Science Translational Medicine | 2011
Yasuteru Urano; Masayo Sakabe; Nobuyuki Kosaka; Mikako Ogawa; Makoto Mitsunaga; Daisuke Asanuma; Mako Kamiya; Matthew Young; Tetsuo Nagano; Peter L. Choyke; Hisataka Kobayashi
A spirocyclic-caged, small-molecule imaging probe fluoresces upon cleavage by a cancer-specific enzyme and can be used during surgical or endoscopic tumor removal procedures. No Tumor Left Behind Although quick action with spray paint usually conjures images of a schoolboy prank, researchers now show that spray painting of tiny tumors might save lives by illuminating these troublemakers that are often overlooked by the naked eye. Ovarian cancer is a deadly gynecological disease, considering its propensity for invading the peritoneal cavity and depositing tumors throughout. Surgeons can miss these disseminated tumors during surgical removal of cancerous lesions, owing to their small size (~1 mm) and unclear borders. To help surgeons visualize and eliminate these clandestine killers, Urano et al. have developed a small-molecule aminopeptidase probe that fluoresces upon contact with cancer cells. The probe—γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG)—is intramolecularly caged, so that it is quenched (nonfluorescent) in its “off” state. When the probe encounters cancer cells, which overexpress the enzyme γ-glutamyltranspeptidase (GGT), the gGlu is cleaved, simultaneously turning “on” the fluorescent HMRG. Urano and colleagues first tested the probe in 11 human ovarian cancer cell lines in vitro and observed rapid fluorescence within 10 min after addition of the imaging agent to the cell cultures. They next moved into several mouse models of disseminated human peritoneal ovarian cancer, using a spray formulation of the probe that allowed the researchers to topically apply the probe during surgery or endoscopy. Within 1 min of spraying the tumors, gGlu-HMRG was enzymatically cleaved, revealing a bright fluorescent region of the peritoneal cavity in which the cancerous lesions were located. These small nodules were quickly and completely removed from living animals with forceps, demonstrating the power of rapid fluorescence-guided tumor resection. This gGlu-based fluorescent probe as well as several other aminopeptidase–based reagents identified by the authors could help surgeons to track down tiny tumors dispersed throughout body cavities, ensuring that no residual tumor is left behind. Complete obliteration of disseminated tumors should improve cancer outcomes after surgery. The ability of the unaided human eye to detect small cancer foci or accurate borders between cancer and normal tissue during surgery or endoscopy is limited. Fluorescent probes are useful for enhancing visualization of small tumors but are typically limited by either high background signal or the requirement for administration hours to days before use. We synthesized a rapidly activatable, cancer-selective fluorescence imaging probe, γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), with intramolecular spirocyclic caging for complete quenching. Activation occurs by rapid one-step cleavage of glutamate with γ-glutamyltranspeptidase (GGT), which is not expressed in normal tissue, but is overexpressed on the cell membrane of various cancer cells, thus leading to complete uncaging and dequenching of the fluorescence probe. In vitro activation of gGlu-HMRG was evident in 11 human ovarian cancer cell lines tested. In vivo in mouse models of disseminated human peritoneal ovarian cancer, activation of gGlu-HMRG occurred within 1 min of topically spraying the tumor, creating high signal contrast between the tumor and the background. The gGlu-HMRG probe is practical for clinical application during surgical or endoscopic procedures because of its rapid and strong activation upon contact with GGT on the surface of cancer cells.
Journal of the American Chemical Society | 2011
Mako Kamiya; Daisuke Asanuma; Erina Kuranaga; Asuka Takeishi; Masayo Sakabe; Masayuki Miura; Tetsuo Nagano; Yasuteru Urano
We identified a rhodol bearing a hydroxymethyl group (HMDER) as a suitable scaffold for designing fluorescence probes for various hydrolases. HMDER shows strong fluorescence at physiological pH, but phenolic O-alkylation of HMDER results in a strong preference for the spirocyclic form, which has weak fluorescence. As a proof of concept, we utilized this finding to develop a new fluorescence probe for β-galactosidase. This probe has favorable characteristics for imaging in biological samples: it has good cellular permeability, and its hydrolysis product is well-retained intracellularly. It could rapidly and clearly visualize β-galactosidase activity in cultured cells and in Drosophila melanogaster tissue, which has rarely been achieved with previously reported fluorescence probes.
Journal of the American Chemical Society | 2013
Masayo Sakabe; Daisuke Asanuma; Mako Kamiya; Ryu J. Iwatate; Kenjiro Hanaoka; Takuya Terai; Tetsuo Nagano; Yasuteru Urano
We have synthesized and evaluated a series of hydroxymethyl rhodamine derivatives and found an intriguing difference of intramolecular spirocyclization behavior: the acetylated derivative of hydroxymethyl rhodamine green (Ac-HMRG) exists as a closed spirocyclic structure in aqueous solution at physiological pH, whereas HMRG itself takes an open nonspirocyclic structure. Ac-HMRG is colorless and nonfluorescent, whereas HMRG is strongly fluorescent. On the basis of these findings, we have developed a general design strategy to obtain highly sensitive fluorescence probes for proteases and glycosidases, by replacing the acetyl group of Ac-HMRG with a substrate moiety of the target enzyme. Specific cleavage of the substrate moiety in the nonfluorescent probe by the target enzyme generates a strong fluorescence signal. To confirm the validity and flexibility of our strategy, we designed and synthesized fluorescence probes for leucine aminopeptidase (Leu-HMRG), fibroblast activation protein (Ac-GlyPro-HMRG), and β-galactosidase (βGal-HMRG). All of these probes were almost nonfluorescent due to the formation of spirocyclic structure, but were converted efficiently to highly fluorescent HMRG by the target enzymes. We confirmed that the probes can be used in living cells. These probes offer great practical advantages, including high sensitivity and rapid response (due to regulation of fluorescence at a single reactive site), as well as resistance to photobleaching, and are expected to be useful for a range of biological and pathological investigations.
Nature Communications | 2015
Daisuke Asanuma; Masayo Sakabe; Mako Kamiya; Kyoko Yamamoto; Jun Hiratake; Mikako Ogawa; Nobuyuki Kosaka; Peter L. Choyke; Tetsuo Nagano; Hisataka Kobayashi; Yasuteru Urano
Fluorescence-guided diagnostics is one of the most promising approaches for facile detection of cancer in situ. Here we focus on β-galactosidase, which is overexpressed in primary ovarian cancers, as a molecular target for visualizing peritoneal metastases from ovarian cancers. As existing fluorescence probes are unsuitable, we have designed membrane-permeable HMRef-βGal, in which the optimized intramolecular spirocyclic function affords >1,400-fold fluorescence enhancement on activation. We confirm that HMRef-βGal sensitively detects intracellular β-galactosidase activity in several ovarian cancer lines. In vivo, this probe visualizes metastases as small as <1 mm in diameter in seven mouse models of disseminated human peritoneal ovarian cancer (SHIN3, SKOV3, OVK18, OVCAR3, OVCAR4, OVCAR5 and OVCAR8). Because of its high brightness, real-time detection of metastases with the naked eye is possible. Endoscopic fluorescence detection of metastases is also demonstrated. The results clearly indicate preclinical potential value of the probe for fluorescence-guided diagnosis of peritoneal metastases from ovarian cancers.
Gut | 2013
Makoto Mitsunaga; Nobuyuki Kosaka; Peter L. Choyke; Matthew R. Young; Christopher R. Dextras; Shakir M. Saud; Nancy H. Colburn; Masayo Sakabe; Tetsuo Nagano; Daisuke Asanuma; Yasuteru Urano; Hisataka Kobayashi
Objectives Screening colonoscopy to monitor for early colitis-associated colon cancer (CAC) is difficult due to the aberrant mucosal patterns associated with long-standing colitis. The aim of this study was to develop a rapid fluorescent detection method for use during colonoscopy for improving the detection of CAC utilising a topically applied enzymatically activatable probe (gGlu-HMRG) which fluoresces in the presence of γ-glutamyltranspeptidase (GGT), an enzyme associated with cancer. Methods Expression of GGT in colon cell lines was examined with fluorescence microscopy and flow cytometry. A mouse model (azoxymethane/dextran sulphate sodium) of CAC was used and mice were examined with white light and fluorescence colonoscopy before and after topical gGlu-HMRG administration. Results Expression of GGT, although variable, was higher in human colon cancer cells than normal human colon cells. Using fluorescence colonoscopy in mice, gGlu-HMRG fluorescent lesions were detected 5 min after topical administration and fluorescence persisted for at least 30 min. Fluorescence guided biopsy revealed all fluorescent lesions that contained cancer or dysplasia (n=16), whereas three out of 12 non-fluorescent lesions contained low grade dysplasia and others did not contain neoplastic histology. Microscopic inflammatory infiltration also had variable fluorescence but in general was much lower (∼10-fold) in signal than cancer. Repeat fluorescence endoscopy allowed individual tumours to be monitored. Conclusion These results suggest that gGlu-HMRG can improve endoscopic detection of CAC with a higher target to background ratio than conventional white light colonoscopy. This could be of benefit to patients with long-standing colitis who must undergo repeated screening colonoscopies.
Scientific Reports | 2015
Hiroki Ueo; Yoshiaki Shinden; Taro Tobo; Ayako Gamachi; Mitsuaki Udo; Hisateru Komatsu; Sho Nambara; Tomoko Saito; Masami Ueda; Hidenari Hirata; Shotaro Sakimura; Yuki Takano; Ryutaro Uchi; Junji Kurashige; Sayuri Akiyoshi; Tomohiro Iguchi; Hidetoshi Eguchi; Keishi Sugimachi; Yoko Kubota; Yuichiro Kai; Kenji Shibuta; Yuko Kijima; Heiji Yoshinaka; Shoji Natsugoe; Masaki Mori; Yoshihiko Maehara; Masayo Sakabe; Mako Kamiya; John W. Kakareka; Thomas J. Pohida
We previously developed γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) as a tool to detect viable cancer cells, based on the fact that the enzyme γ-glutamyltranspeptidase (GGT) is overexpressed on membranes of various cancer cells, but is not expressed in normal tissue. Cleavage of the probe by GGT generates green fluorescence. Here, we examined the feasibility of clinical application of gGlu-HMRG during breast-conserving surgery. We found that fluorescence derived from cleavage of gGlu-HMRG allowed easy discrimination of breast tumors, even those smaller than 1 mm in size, from normal mammary gland tissues, with 92% sensitivity and 94% specificity, within only 5 min after application. We believe this rapid, low-cost method represents a breakthrough in intraoperative margin assessment during breast-conserving surgery.
British Journal of Surgery | 2013
Suguru Yamashita; Masayo Sakabe; Takeaki Ishizawa; Kiyoshi Hasegawa; Yasuteru Urano; Norihiro Kokudo
Pancreatic fistula (PF) remains the most serious complication after digestive surgery. It is difficult to prevent because of the inability to visualize the leakage of pancreatic juice during surgery or to evaluate the protease activity of leaked fluid, which is responsible for PF formation.
Scientific Reports | 2016
Yoshiaki Shinden; Hiroki Ueo; Taro Tobo; Ayako Gamachi; Hisateru Komatsu; Sho Nambara; Tomoko Saito; Masami Ueda; Hidenari Hirata; Shotaro Sakimura; Yuki Takano; Ryutaro Uchi; Junji Kurashige; Sayuri Akiyoshi; Tomohiro Iguchi; Hidetoshi Eguchi; Keishi Sugimachi; Yoko Kubota; Yuichiro Kai; Kenji Shibuta; Yuko Kijima; Heiji Yoshinaka; Shoji Natsugoe; Masaki Mori; Yoshihiko Maehara; Masayo Sakabe; Mako Kamiya; John W. Kakareka; Thomas J. Pohida; Peter L. Choyke
Sentinel lymph node biopsy is performed as a standard procedure in breast cancer surgery, and the development of quick and simple methods to detect metastatic lesions is in high demand. Here, we validated a new fluorescent method using γ-glutamyl hydroxymethyl rhodamine green to diagnose metastatic lymph nodes in breast cancer. One hundred and forty-nine lymph nodes from 38 breast cancer patients were evaluated in this study. Comparison of fluorescent and pathological images showed that this fluorescent method was successful for visualizing breast cancer cells in lymph nodes. This method had a sufficiently high sensitivity (97%), specificity (79%) and negative predictive value (99%) to render it useful for an intraoperative diagnosis of cancer. These preliminary findings suggest that this novel method is useful for distinguishing non-cancerous specimens from those in need of careful examination and could help save time and cost for surgeons and pathologists.
Optical Molecular Probes, Imaging and Drug Delivery | 2015
Yasuteru Urano; Mako Kamiya; Shin-nosuke Uno; Masayo Sakabe
We have established versatile and flexible design strategies for novel organic fluorogenic probes based on intramolecular spirocyclization. First-in-class probes for rapid detection of in vivo tiny tumors and for super-resolution imaging were successfully developed.
Archive | 2015
Suguru Yamashita; Takeaki Ishizawa; Masayo Sakabe; Mako Kamiya; Yasuteru Urano; Norihiro Kokudo
Pancreatic fistula remains the most serious complication after digestive surgery. This is mainly because there are no techniques to identify pancreatic leak from the pancreatic stump during surgery. Nor have there been any techniques for rapid evaluation of protease activity in leaking fluid during surgery that can cause severe tissue damage. We have designed and developed a novel fluorescence probe (glutaryl phenylalanine hydroxymethyl rhodamine green) that is activated by chymotrypsin. The use of this novel probe is expected to result in a reduced incidence of pancreatic fistula and operative mortality after digestive surgery.